Pulse Biosciences Files 8-K on Material Agreement
Ticker: PLSE · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.001, $60.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-K, financial-reporting
TL;DR
Pulse Biosciences filed an 8-K on July 15, 2024, for a material definitive agreement.
AI Summary
On July 15, 2024, Pulse Biosciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers results of operations and financial condition, along with financial statements and exhibits. Specific details regarding the agreement, financial results, or exhibits were not provided in the excerpt.
Why It Matters
This filing indicates a significant business development for Pulse Biosciences, Inc., potentially impacting its operations and financial standing.
Risk Assessment
Risk Level: medium — An 8-K filing signals a material event, which could introduce uncertainty or opportunity, warranting a medium risk assessment until more details are known.
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- July 15, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-37744 (identifier) — Commission File Number
- 46-5696597 (identifier) — IRS Employer Identification No.
- 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — Address of Principal Executive Offices
FAQ
What is the nature of the material definitive agreement filed by Pulse Biosciences, Inc. on July 15, 2024?
The provided excerpt does not specify the details of the material definitive agreement.
What are the key financial results or conditions reported by Pulse Biosciences, Inc. in this 8-K filing?
The excerpt mentions 'Results of Operations and Financial Condition' as an item covered, but does not provide specific financial details.
Does the 8-K filing include any new financial statements or exhibits?
Yes, the filing indicates that 'Financial Statements and Exhibits' are included as part of the report.
What is the principal executive office address for Pulse Biosciences, Inc. as listed in the filing?
The principal executive office address is listed as 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
What is the Commission File Number for Pulse Biosciences, Inc.?
The Commission File Number for Pulse Biosciences, Inc. is 001-37744.
Filing Stats: 2,362 words · 9 min read · ~8 pages · Grade level 12.6 · Accepted 2024-07-15 07:10:01
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 par value per share PLSE The Nasdaq
- $60.0 million — ng an aggregate offering price of up to $60.0 million (the "Shares"). The Company is not ob
Filing Documents
- d867904d8k.htm (8-K) — 59KB
- d867904dex11.htm (EX-1.1) — 141KB
- d867904dex51.htm (EX-5.1) — 10KB
- g867904g16w89.jpg (GRAPHIC) — 11KB
- 0001193125-24-178827.txt ( ) — 394KB
- plse-20240715.xsd (EX-101.SCH) — 3KB
- plse-20240715_lab.xml (EX-101.LAB) — 18KB
- plse-20240715_pre.xml (EX-101.PRE) — 11KB
- d867904d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of the Company, and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the Company's estimated preliminary financial information described above, including the Company's GAAP and non-GAAP costs and expenses and net loss, depreciation and amortization, stock-based compensation, and cash and cash equivalents for the quarterly period ended June 30, 2024. A more complete description of these and other material risks can be found in the Company's filings with the SEC under the heading "Risk Factors." Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by the Company. The Company does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Equity Distribution Agreement, dated July 15, 2024, by and among Pulse Biosciences, Inc. and Canaccord Genuity LLC and Needham & Company, LLC. 5.1 Opinion of Baker & Hostetler LLP 23.1 Consent of Baker & Hostetler LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. PULSE BIOSCIENCES, INC. Date: July 15, 2024 By: /s/ Burke T. Barrett President and Chief Executive Officer (Principal Executive and Principal Financial Officer)